Immunotherapy for early stage colorectal cancer: A glance into the future

Romain Cohen, Qian Shi, Thierry André

Research output: Contribution to journalReview articlepeer-review


Immune checkpoint inhibitors (ICI) have reshaped therapeutic strategies for cancer patients. The development of ICI for early stage colorectal cancer is accompanied by specific challenges: (i) the selection of patients who are likely to benefit from these treatments, i.e., patients with tumors harboring predictive factors of efficacy of ICI, such as microsatellite instability and/or mismatch repair deficiency (MSI/dMMR), or other potential parameters (increased T cell infiltration using Immunoscore® or others, high tumor mutational burden, POLE mutation), (ii) the selection of patients at risk of disease recurrence (poor prognostic features), and (iii) the choice of an accurate clinical trial methodological framework. In this review, we will discuss the ins and outs of clinical research of ICI for early stage MSI/dMMR CC patients in adjuvant and neoadjuvant settings. We will then summarize data that might support the development of ICI in localized colorectal cancer beyond MSI/dMMR.

Original languageEnglish (US)
Article number1990
Pages (from-to)1-14
Number of pages14
Issue number7
StatePublished - Jul 2020


  • Immunoscore
  • Microsatellite instability
  • Mismatch repair deficiency
  • Oxaliplatin
  • Stage III

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Immunotherapy for early stage colorectal cancer: A glance into the future'. Together they form a unique fingerprint.

Cite this